Protagonist Therapeutics Stock Price, News & Analysis (NASDAQ:PTGX) $18.21 +0.52 (+2.94%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$17.91▼$18.6850-Day Range$14.05▼$18.2152-Week Range$7.34▼$30.10Volume447,136 shsAverage Volume1.10 million shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$35.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Protagonist Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside93.6% Upside$35.25 Price TargetShort InterestHealthy6.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.76) to ($2.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector626th out of 949 stocksPharmaceutical Preparations Industry296th out of 439 stocks 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.25, Protagonist Therapeutics has a forecasted upside of 93.6% from its current price of $18.21.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.33% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Protagonist Therapeutics has recently decreased by 7.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 2.7 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Protagonist Therapeutics this week, compared to 2 articles on an average week.Search Interest19 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from ($1.76) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Protagonist Therapeutics Stock (NASDAQ:PTGX)Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More PTGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Stock News HeadlinesNovember 27, 2023 | finance.yahoo.comProtagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with DeucravacitinibNovember 16, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Reports Granting of Inducement AwardsDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 16, 2023 | markets.businessinsider.comProtagonist Therapeutics Earns ‘Buy’ Rating on Strength of Drug Pipeline and Potential RoyaltiesNovember 9, 2023 | finance.yahoo.comProtagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)November 9, 2023 | finance.yahoo.comDoes Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect?November 4, 2023 | finance.yahoo.comProtagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial ResultsNovember 4, 2023 | markets.businessinsider.comProtagonist Therapeutics’ Promising Future: Psoriasis Drug Development and Potential Blockbuster Market OpportunitiesDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 3, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Protagonist TherapeuticsNovember 2, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 2, 2023 | finance.yahoo.comProtagonist Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 1, 2023 | finance.yahoo.comProtagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe PsoriasisNovember 1, 2023 | finance.yahoo.comProtagonist Therapeutics to Participate in Upcoming Investor ConferencesOctober 31, 2023 | benzinga.comProtagonist Therapeutics Stock (NASDAQ:PTGX), Analyst Ratings, Price Targets, PredictionsOctober 30, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of DirectorsOctober 30, 2023 | finance.yahoo.comProtagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of DirectorsOctober 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Ventyx Biosciences (VTYX)October 10, 2023 | markets.businessinsider.comProtagonist Therapeutics’ Promising Drug JNJ-2113: A Potential Market Leader and Revenue BoosterOctober 9, 2023 | markets.businessinsider.comPromising Clinical Trials and Revenue Potential Propel Buy Rating for Protagist TherapeuticsOctober 9, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Announces Advancement of JNJ-2113 Across Multiple IndicationsOctober 9, 2023 | finance.yahoo.comProtagonist Announces Advancement of JNJ-2113 Across Multiple IndicationsSeptember 26, 2023 | msn.comJP Morgan Maintains Protagonist Therapeutics (PTGX) Overweight RecommendationSeptember 5, 2023 | finance.yahoo.comProtagonist Therapeutics to Present at Upcoming Investor ConferencesAugust 9, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Receives $34 Million from Warrant ExercisesAugust 9, 2023 | finance.yahoo.comProtagonist Receives $34 Million from Warrant ExercisesAugust 4, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), Dynavax (DVAX)See More Headlines Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees111Year FoundedN/APrice Target and Rating Average Stock Price Target$35.25 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside+93.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-127,390,000.00 Net MarginsN/A Pretax Margin-16,319.91% Return on Equity-54.66% Return on Assets-49.37% Debt Debt-to-Equity RatioN/A Current Ratio11.66 Quick Ratio11.66 Sales & Book Value Annual Sales$26.58 million Price / Sales39.52 Cash FlowN/A Price / Cash FlowN/A Book Value$5.24 per share Price / Book3.48Miscellaneous Outstanding Shares57,680,000Free Float54,794,000Market Cap$1.05 billion OptionableNot Optionable Beta1.85 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 66)CEO, President, Secretary & Director Comp: $883.46kDr. Suneel K. Gupta Ph.D. (Age 65)Chief Development Officer Comp: $640.89kDr. Mark Smythe Ph.D. (Age 58)Founder & VP Technology Mr. Asif Ali (Age 49)Executive VP & Chief Financial Officer Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 52)Executive VP & General Counsel Ms. Carena SpiveySenior Vice President of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 59)Executive VP & Chief Drug Discovery and Preclinical Development Officer Dr. Scott Eric Plevy M.D.Executive VP & Therapeutic Head of GastroenterologyMr. Carter J. King (Age 52)Senior Vice President of Business Development More ExecutivesKey CompetitorsDay One BiopharmaceuticalsNASDAQ:DAWNLigand PharmaceuticalsNASDAQ:LGNDANI PharmaceuticalsNASDAQ:ANIPAvadel PharmaceuticalsNASDAQ:AVDLBelite BioNASDAQ:BLTEView All CompetitorsInstitutional OwnershipDeutsche Bank AGSold 789,411 shares on 11/24/2023Ownership: 0.125%Public Sector Pension Investment BoardSold 97,000 shares on 11/22/2023Ownership: 0.085%Walleye Capital LLCBought 90,555 shares on 11/21/2023Ownership: 0.232%Walleye Trading LLCSold 8,900 shares on 11/21/2023Ownership: 0.000%Jacobs Levy Equity Management Inc.Sold 17,476 shares on 11/17/2023Ownership: 0.224%View All Institutional Transactions PTGX Stock Analysis - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price target for 2024? 4 brokerages have issued 1 year price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $38.00. On average, they predict the company's share price to reach $35.25 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2023? Protagonist Therapeutics' stock was trading at $10.91 at the beginning of the year. Since then, PTGX shares have increased by 66.9% and is now trading at $18.21. View the best growth stocks for 2023 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Thursday, November, 2nd. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10. What ETF holds Protagonist Therapeutics' stock ? Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Kynam Capital Management LP (3.15%), Braidwell LP (1.92%), 683 Capital Management LLC (1.27%), Adage Capital Partners GP L.L.C. (1.21%), Northern Trust Corp (0.98%) and Hsbc Holdings PLC (0.96%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PTGX) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.